The KRT19 Knockout 143B Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 143B osteosarcoma cell line, engineered for loss-of-function studies of the keratin 19 (KRT19) gene. This product enables controlled disruption of the intermediate filament protein KRT19, facilitating investigations into its roles in cell architecture, adhesion, and signal transduction within a mesenchymal tumor context. The polyclonal format captures the heterogeneity of CRISPR-mediated gene disruption, providing a robust model system for evaluating phenotypic outcomes without clonal selection artifacts.
The 143B host cell line is a widely used model of osteosarcoma, originally derived from the HOS (human osteosarcoma) cell line and characterized by its osteoblast-like properties and high metastatic potential. These cells exhibit rapid proliferation, anchorage-independent growth, and the capacity for both local invasion and distant metastasis in vivo, making them particularly relevant for studying bone cancer progression. The 143B line retains key mesenchymal features, offering a unique platform to explore the functional consequences of ectopic keratin expression in a non-epithelial background.
KRT19, a type I intermediate filament protein, typically functions in epithelial cells to maintain cytoarchitecture and mechanical integrity through heterodimerization with its type II partner KRT8 and association with cytoskeletal linkers such as plectin. In the 143B context, KRT19 expression is subject to regulation by transcription factors including p63, ??-catenin, and AP-1, and by growth factor signals like EGF and TGF-??. Downstream, KRT19 influences cell behavior via interactions with integrin ??1, FAK, and RhoA, thereby modulating core pathways such as Wnt signaling and PI3K-AKT, which are critically involved in epithelial-mesenchymal transition (EMT) and tumor cell dissemination.
Disruption of KRT19 in 143B cells is anticipated to derange intermediate filament organization, thereby impairing cell-matrix adhesion and altering migratory properties. Given the central role of KRT19 in bridging cytoskeletal dynamics and signaling, its knockout serves as a strategic model to dissect the molecular underpinnings of EMT-like processes in osteosarcoma, a tumor type not classically associated with keratin expression. This system also allows investigation of how keratin network perturbation affects ??-catenin/FAK-mediated signaling cascades and RhoA-dependent cytoskeletal rearrangements, providing insights into metastatic mechanisms.
The KRT19 Knockout 143B Polyclonal Cells are ideally suited for a range of experimental methodologies, including western blotting and RT-qPCR for confirming target disruption, immunofluorescence to visualize keratin network dissolution, and functional assays such as transwell migration, invasion, MTT proliferation, and soft agar colony formation to assess metastatic and tumorigenic capacity. Moreover, these cells can be employed in in vivo metastasis models to evaluate the contribution of KRT19 to osteosarcoma progression and to test pharmacological interventions. For further technical details, please contact Ascent Research.
